The history of the cholinergic hypothesis

Behavioural Brain Research

Volumn 221, Issue 2, 2011, Pages 334-340

  Contestabile, Antonio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Alzheimer's disease; Animal models; Cholinergic system; Clinical studies; Dementia

Indexed keywords

ACETYLCHOLINE; AMYLOID BETA PROTEIN; CHOLINE ACETYLTRANSFERASE; CHOLINERGIC RECEPTOR STIMULATING AGENT; DONEPEZIL; GALANTAMINE; NERVE GROWTH FACTOR; RIVASTIGMINE; TACRINE; TAU PROTEIN; VESICULAR ACETYLCHOLINE TRANSPORTER;

ACETYLCHOLINE RELEASE; ALZHEIMER DISEASE; BRAIN REGION; CHOLINERGIC NERVE CELL; CHOLINERGIC SYSTEM; CHOLINERGIC TRANSMISSION; CHROMOSOME 16; CHROMOSOME 21; COGNITION; DEGENERATIVE DISEASE; DEMENTIA; DOWN SYNDROME; DRUG EFFICACY; ENZYME ACTIVITY; HUMAN; IMMUNOREACTIVITY; MILD COGNITIVE IMPAIRMENT; NEUROTRANSMISSION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

ACETYLCHOLINE; ALZHEIMER DISEASE; ANIMALS; BRAIN; CHOLINERGIC FIBERS; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DOWN SYNDROME; HUMANS; RESEARCH;

EID: 79955738773     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2009.12.044     Document Type: Review

References (129)

1. Alzheimer A. Über einen eigenartigen schweren Erkrankungsprozeß der Hirnrinde. Neurologisches Centralblatt 1906, 23:1129-1136.
2. Alzheimer A. Über eigenartige Krankheitsfälle des späteren Alters. Zeitschrift für die Gesamte Neurologie und Psychiatrie 1911, 4:356-385.
3. Amenta F., Parnetti L., Gallai V., Wakllin A. Treatment of cognitive dysfunction associated with Alzheimer's disease with cholinergic precursors. Ineffective treatments or inappropriate approaches?. Mech Ageing Dev 2001, 122:2025-2040.
4. Arciniegas D.B. The cholinergic hypothesis of cognitive impairment caused by traumatic brain injury. Curr Psychiatry Rep 2003, 5:391-399.
5. Arendt T., Bigl V., Arendt A., Tennstedt A. Loss of neurons in the nucleus basalis of Meynert in Alzheimer's disease, paralysis agitans and Korsakoff's disease. Acta Neuropathol 1983, 61:101-108.
6. Avrampoulos D. Genetics of Alzheimer's disease: recent advances. Genome Med 2009, 1:34.
7. Berman J.A., Talmage D.A., Role L.W. Cholinergic circuits and signaling in the pathophysiology of schizophrenia. Int Rev Neurobiol 2007, 78:193-223.
8. Bartus R. Physostigmine and memory: effects in young and aged nonhuman primates. Science 1979, 270:1087-1089.
9. Bartus R. Cholinergic treatment of age-related memory disturbances: dead or barely coming of age?. Treatment developing strategies for Alzheimer's disease 1986, 421-450. Powley Associated, Madison, CT. T. Crook (Ed.).
10. Bartus R. On neurodegenerative diseases, models and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 2000, 163:495-529.
11. Bartus R.T., Dean R.L., Beer B., Lippa A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982, 217:408-417.
12. Bartus R., Dean R., Flicker C Cholinergic psychopharmacology: an integration of human and animal research in memory. Psychopharmacology. A third generation of progress 1987, 219-232. Raven Press, New York. E. Usdin (Ed.).
13. Battaglia M. Beyond the usual suspects: a cholinergic route for panic attacks. Mol Psychiatry 2002, 7:239-246.
14. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006, 1.
15. Boegman R.I., Cockhill I., Jhamandas K., Beninger R.J. Excitotoxic lesions of rat basal forebrain: differential effects on choline acetyltransferase in the cortex and amygdala. Neuroscience 1992, 51:129-135.
16. Borchelt D.R., Ratoviski T., vanLare J., Lee M.K., Gonzales V., Jenkins N.A., et al. Accelerated amyloid deposition in the brains of transgenic mice co-expressing mutant presenilin 1 and amyloid precursor protein. Neuron 1997, 19:939-945.
17. Bowen D.M., Smith C.B., White P., Davison A.N. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 1976, 99:459-496.
18. Burghaus L., Schutz U., Krempel U., DeVos R.A.I., Jansen-Steur E.N.H., Wevers A., et al. Quantitative assessment of nicotinic acetylcholine receptor proteins in the cerebral cortex of Alzheimer patients. Mol Brain Res 2000, 76:385-388.
19. Calhoun M.E., Wiederhold K.H., Abramowski D., Phinney A.L., Probst A., Sturchler-Pierrat C., et al. Neuron loss in APP transgenic mice. Nature 1998, 395:755-756.
20. Capsoni S., Ugolini G., Comparini A., Ruberti F., Berardi N., Cattaneo A. Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice. Proc Natl Acad Sci USA 2000, 97:6826-6831.
21. Casanova M.F., Walker L.C., Withehous P.J., Price D.L. Abnormalities of the nucleus basalis in Down's syndrome. Ann Neurol 1985, 18:310-313.
22. Chen G., Chen K.S., Knox J., Inglis J., Bernard A., Martin S.J., et al. A learning deficit related to age and β-amyloid plaques in a mouse model of Alzheimer's disease. Nature 2000, 405:975-979.
23. Chu Y., Cochran E.J., Bennet D.A., Mufson E.J., Kprdower J.H. Downregulation of trkA mRNA within nucleus basalis neurons in individuals with mild cognitive impairment and Alzheimer's disease. J Comp Neurol 2001, 443:136-153.
24. Contestabile A., Ciani E., Contestabile A. The place of choline acetyltransferase activity measurement in the " cholinergic hypothesis" of neurodegenerative diseases. Neurochem Res 2008, 33:318-327.
25. Contestabile A., Fila T., Bartesaghi R., Contestabile A., Ciani E. Choline acetyltransferase activity at different ages in brain of Ts65Dn mice, an animal model for Down's syndrome and related neurodegenerative diseases. J Neurochem 2006, 97:515-526.
26. Contestabile A., Fila T., Ceccarelli C., Bonasoni P., Bonapace L., Santini D., et al. Cell cycle alteration and decreased cell proliferation in the hippocampal dentate gyrus and in the neocortical germinal matrix of fetuses with Down syndrome and in Ts65Dn mice. Hippocampus 2007, 17:665-678.
27. Contestabile A., Fila T., Bartesaghi R., Ciani E. Cell cycle elongation impairs proliferation of cerebella granule cell precursors in the Ts65Dn mouse, an animal model for Down syndrome. Brain Pathol 2009, 19:224-237.
28. Cooper J.D., Salhei A., Delcroix J.-D., Howe C.L., Belichenko P.V., Chua-Couzens J., et al. Failed retrograde transport of NGF in a mouse model of Down's syndrome: reversal of cholinergic neurodegenerative phenotypes following NGF infusion. Proc Natl Acad Sci USA 2001, 98:10439-10444.
29. Counts S.E., Mufson E.J. The role of nerve growth factor receptors in cholinergic basal forebrain degeneration in prodromal Alzheimer's disease. J Neuropathol Exp Neurol 2005, 64:263-272.
30. Court J.A., Lloyd S., Thomas N., Piggot M.A., Marshall E.F., Morris C.M., et al. Dopamine and nicotinic receptor binding and the levels of dopamine and homovanilic acid in human brain related to tobacco use. Neuroscience 1998, 87:63-78.
31. Dai J., Buijs R.M., Kamphorst W., Swaab D.F. Impaired axonal transport of cortical neurons in Alzheimer's disease is associated with neuropathological changes. Brain Res 2002, 948:138-144.
32. Dale H.H. The action of certain esters and ethers of choline, and their relation to muscarine. J Pharmacol Exp Ther 1914, 6:147-190.
33. Dale H.H., Dudley H.W. The presence of histamine and acetylcholine in the spleen of the ox and horse. J Physiol 1929, 68:97-123.
34. Davies P., Maloney A.J.F. Selective loss of central cholinergic neurones in Alzheimer's disease. Lancet 1976, 2:1403.
35. Davis K.L., Mohs R.C., Marin D., Purohit D.P., Perl D.P., Lantz M., et al. Cholinergic markers in elderly patients with early signs of Alzheimer's disease. J Am Med Assoc 1999, 281:1401-1406.
36. Davisson M.T., Schmidt C., Akeson E.C. Segmental trisomy of murine chromosome 16: a new model for studying Down syndrome. Prog Clin Biol Res 1990, 360:263-280.
37. DeKosky S.T., Ikonomovic M.D., Styren S.D., Beckett L., Wisniewski S., Bennet D.A., et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 2002, 51:145-155.
38. Dilsaver S.C., Coffman J.A. Cholinergic hypothesis of depression: a reappraisal. J Clin Psychopharmacol 1989, 9:173-179.
39. Dournaud P., Delaere P., Hauw J.J., Epelbaum J. Differential correlation between neurochemical deficits, neuropathology, and cognitive status in Alzheimer's disease. Neurobiol Aging 1995, 16:817-823.
40. Drachman D.A., Leavitt J. Human memory and the cholinergic system. Arch Neurol 1974, 30:113-121.
41. Dunbar G., Boeijinga P.H., Demazieres A., Cisterni C., Kuchibhatla R., Wesnes K., et al. Effects of TC-1734 (AZD3480, a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers. Psychopharmacology 2007, 191:919-929.
42. Dunnet S., Whishaw I., Jones G., Bunch S. Behavioral, biochemical and histochemical effects of different neurotoxic amino acids injected into the nucleus basalis magnocellularis of rats. Neuroscience 1987, 20:653-669.
43. Dunnet S., Everitt B., Robbins T. The basal forebrain-cortical cholinergic system: interpreting the functional consequences of excitotoxic lesions. Trends Neurosci 1991, 14:494-501.
44. Efange S.M., Garland E.M., Staley J.K., Khare A.B., Mash D.C. Vesicular acetylcholine transporter density and Alzheimer's disease. Neurobiol Aging 1997, 18:407-413.
45. Eleuteri S., Monti B., Brignani S., Contestabile A. Chronic dietary administration of valproic acid protects neurons of the rat nucleus basalis magnocellularis from ibotenic acid neurotoxicity. Neurotoxicol Res 2009, 15:127-132.
46. Fibiger H.C. Cholinergic mechanisms in learning, memory and dementia: a review of recent evidence. Trends Neurosci 1991, 14:220-223.
47. Flieder J.L., Epstein C.J., Rapoport S.I., Caviedes R., Caviedes P. Regional alterations of cholinergic function in central neurons of trisomy 16 mouse fetuses, an animal model of human trisomy 21 (Down syndrome). Brain Res 1994, 658:27-32.
48. Fodale V., Mafrica F., Caminiti V., Grasso G. The cholinergic system in Down's syndrome. J Intellect Disabil 2006, 10:261-274.
49. Frolich L. The cholinergic pathology in Alzheimer's disease-discrepancies between clinical experience and pathophysiological findings. J Neural Transm 2002, 109:1003-1014.
50. Gallagher M., Colombo P.J. Ageing: the cholinergic hypothesis of cognitive decline. Curr Opin Neurobiol 1995, 5:161-168.
51. Gau J.T., Steinhilb M.L., Kao T.C., D'Amato C.J., Gaut J.R., Frey K.A., et al. Stable beta secretase activity and presynaptic cholinergic markers during progressive central nervous system amyloidogenesis in TG2576 mice. Am J Pathol 2002, 160:731-738.
52. Geerts H. Ispronicline (targacept). Curr Opin Investig Drugs 2006, 7:60-69.
53. Geula C., Mesulam M.M. Systematic reginal variations in the loss of cortical cholinergic fibers in Alzheimer's disease. Cereb Cortex 1996, 6:165-177.
54. German D.C., Yazdani U., Speciale S.G., Pasbakhsh P., Games D., Liang C.L. Cholinergic neuropathology in a mouse model of Alzheimer's disease. J Comp Neurol 2003, 462:371-381.
55. Gibson G.E., Sheu K.F., Blass J.P., Baker A., Carlson K.C., Harding B., et al. Reduced activities of thiamine-dependent enzymes in the brain and peripheral tissues of patients with Alzheimer's disease. Arch Neurol 1988, 45:836-840.
56. Gilmor M.I., Erickson J.D., Varoqui H., Hersh L.B., Bennet D.A., Cochran E.J., et al. Preservation of nucleus basalis neurons containing choline acetyltransferase and the vesicular acetylcholine transporter in elderly with mild cognitive impairment and early Alzheimer's disease. J Comp Neurol 2000, 427:19-30.
57. Gomez-Isla T., Price J.L., McKeed D.W., Morris J.C., Growdon J.H., Hyman B.T. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci 1996, 16:4491-4500.
58. Goodridge H., Reynolds G.P., Czudek C., Calcutt N.A., Benton M. Alzheimer-like neurotransmitter deficits in adult Down's syndrome brain tissue. J Neurol Neurosurg Psychiatry 1987, 50:775-778.
59. Granholm A.C., Sanders L.A., Crnic L.S. Loss of cholinergic phenotype in basal forebrain coincides with cognitive decline in a mouse model of Down's syndrome. Exp Neurol 2000, 161:647-663.
60. Hardy J., Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 1991, 12:383-388.
61. Hardy J., Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256:184-185.
62. Hayes A., Batshaw M.L. Down syndrome. Pediatr Clin North Am 1993, 40:523-529.
63. Hernandez D., Sugaya K., Qu T., McGowan E., Duff K., McKinney M. Survival and plasticity of basal forebrain cholinergic system in mice transgenic for presenilin-1 and amyloid protein mutant genes. Neuroreport 2001, 12:1377-1384.
64. Hokfelt T. Looking at neurotransmitters in the microscope. Prog Neurobiol 2009, October 21 [Epub ahead of print].
65. Holtzman D.M., Kilbridge J., Chen K.S., Rabin J., Luche R., Carlson E., et al. Preliminary characterization of the central nervous system in partial trisomy 16 mice. Prog Clin Biol Res 1995, 393:227-240.
66. Hshie T.T., Fong T.G., Marcantonio E.R., Inouye S.K. Cholinergic deficiency hypothesis in delirium: a synthesis of current evidence. J Gerontol A Biol Sci Med Sci 2008, 63:764-772.
67. Hunter C.L., Bimonte H.A., Granholm A.C. Behavioral comparison of 4- and 6-month-old Ts65Dn mice: age-related impairments in working and reference memory. Behav Brain Res 2003, 138:121-131.
68. Ikonomovic M.D., Mufson E.J., Wuu J., Cochran E.J., Bennet D.A., DeKosky S.T. Cholinergic plasticity in hippocampus with mild cognitive impairment: correlation with Alzheimer's neuropathology. J Alzheimer's Dis 2003, 5:39-48.
69. Irizzarry M.C., Soriano F., McNamara M., Page K.J., Scenk D., Games D., et al. Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloyd precursor protein V717F (PDAPP) transgenic mouse. J Neurosci 1997, 17:7053-7059.
70. Jette N., Cole M.S., Fahnestock M. NGF mRNA is not decreased in frontal cortex from Alzheimer's disease patients. Mol Brain Res 1994, 25:242-250.
71. Kish S.J., Robitaille Y., el-Awar M., Deck J.H., Simmons J., Schut L., et al. Non-Alzheimer-type pattern of brain cholineacetyltransferase reduction in dominantly inherited olivopontocerebellar atrophy. Ann Neurol 1989, 26:362-367.
72. Kish S., Karlinsky H., Becker L., Gilbert J., Rebbetoy M., Chang L.J., et al. Down's syndrome individuals begin life with normal levels of brain cholinergic markers. J Neurochem 1989, 52:1183-1187.
73. Kordower J.H., Chu Y., Stebbins J.T., DeKosky S.T., Cochran E.J., Bennet D., et al. Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment. Ann Neurol 2001, 49:202-213.
74. Loewi O. Uber humorale Ubertragbarkeit der Herznervenwirkung. Pflugers Arch 1921, 189:239-242.
75. Longo V. Behavioral and electroencephalographic effects of atropine and related compounds. Pharmacol Rev 1966, 18:965-996.
76. Lopez-Pousa S., Olmo J.P., Franch J.V., Estrada A.T. Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil or galantamine. Age Aging 2006, 35:365-371.
77. Luppi P.H., Gervasoni D., Verret L., Goutagny R., Peyron C., Salvert D., et al. Paradoxical (REM) sleep genesis: the switch from an aminergic-cholinergic to a GABAergic-glutamatergic hypothesis. J Physiol (Paris) 2006, 100:271-283.
78. Mann D.M., Esiri M.M. The pattern of acquisition of plaques and tangles in the brain of patients under 50 years of age with Down's syndrome. J Neurol Sci 1989, 89:169-179.
79. Milner T.A., Aoki C., Sheu K.F., Blass J.P., Pickel V.M. Light microscopic immunocytochemical localization of pyruvate dehydrogenase complex in rat brain: topographical distribution and relation to cholinergic and catecholaminergic nuclei. J Neurosci 1987, 7:3171-3190.
80. Mufson E.J., Bothwell M., Hersh L.B., Kordower J.H. Nerve growth factor receptor immunoreactivity profiles in the normalaged human basal forebrain colocalization with cholinergic neuron. J Comp Neurol 1989, 285:196-217.
81. Mufson E.J., Li J.M., Sobreviela T., Kordower J.H. Decreased trkA gene expression within basal forebrain neurons in Alzheimer's disease. Neuroreport 1996, 8:25-29.
82. Mufson E.J., Kroin J.S., Sendera T.J., Sobreviela T. Distribution and retrograde transport of trophic factors in the central nervous system: functional implications for the treatment of neurodegenerative diseases. Prog Neurobiol 1999, 57:451-484.
83. Mufson E.J., Ma S.Y., Cochran E.J., Bennet D.A., Beckett L.A., Jaffar S., et al. Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer's disease. J Comp Neurol 2000, 427:19-30.
84. Mufson E.J., Ma S.Y., Dills J., Cochran E.J., Leurgans S., Wuu J., et al. Loss of basal forebrain p75NTR immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease. J Comp Neurol 2002, 443:136-153.
85. Mufson E.J., Ginsberg S., Ikonomovic M.D., DeKosky S.T. Human cholinergic basal forebrain: chemoanatomy and neurologic dysfunction. J Chem Neuroanat 2003, 26:233-242.
86. Murdoch I., Perry E.K., Court J.A., Graham D.I., Dewar D. Cortical cholinergic dysfunction after human head injury. J Neurotrauma 1998, 15:295-305.
87. Musial A., Bajda M., Malawska B. Recent developments in cholinesterase inhibitors for Alzheimer's disease treatment. Curr Med Chem 2007, 14:2654-2679.
88. Nilsson L., Norberg A., Hardy J., Wester P., Winblad B. Physostigmine restores [3H]-acetylcholine efflux from Alzheimer's brain slices to normal level. J Neural Transm 1986, 67:275-285.
89. Nitsch R.M. From acetylcholine to amyloid: neurotransmitters and the pathology of Alzheimer's disease. Neurodegeneration 1996, 5:477-482.
90. Nitsch R.M., Slack B.E., Wurtman R.J., Growdon J.H. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 1992, 258:304-307.
91. Nordberg A., Alafuzoff I., Winblad B. Nicotinic and muscarinic subtypes in the human brain: changes with aging and dementia. J Neurosci Res 1992, 31:103-111.
92. Oddo S., Caccamo A., Sheperd J.D., Murphy M.P., Golde T.E., Kayed R., et al. Triple transgenic model of Alzheimer's disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Neuron 2003, 409-421.
93. Pakaski M., Kalman J. Interactions between the amyloid and cholinergic mechanisms in Alzheimer's disease. Neurochem Int 2008, 53:103-111.
94. Passavento E., Capsoni S., Domenici L., Cattaneo A. Acute cholinergic rescue of synaptic plasticity in the neurodegenerating cortex of anti-nerve growth factor mice. Eur J Neurosci 2002, 15:1030-1036.
95. Perry E.K., Gibson P.H., Blessed G., Perry R.H., Tomlinson B.E. Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. J Neurol Sci 1977, 34:247-265.
96. Perry E.K., Tomlinson B.E., Blessed G., Bergmann K., Gibson P.H., Perry R.H. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 1978, 2:1457-1459.
97. Perry E.K., Curtis M., Dick D.J., Candy J.M., Atack J.R., Bloxham C.A., et al. Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J Neurol Neurosurg Psychiatry 1985, 48:413-421.
98. Raschetti R., Albanese E., Vanacore N., Maggini M. Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS Med 2007, 4:e338.
99. Readler T.J., Bymaster F.P., Tandon R., Copolov D., Dean B. Towards a muscarinic hypothesis of schizophrenia. Mol Psychiatry 2007, 12:232-246.
100. Roberson R.M., Harrel L.E. Cholinergic activity and amyloid precursor protein metabolism. Brain Res Rev 1997, 25:59-60.
101. Ruberti F., Capsoni S., Comparini A., Di Daniel E., Franzot J., Gonfloni S., et al. Phenotypic knockout of nerve growth factor in adult transgenic mice reveals severe deficits in basal forebrain cholinergic neurons, cell death in the spleen and skeletal muscle distrophy. J Neurosci 2000, 20:2581-2601.
102. Rylett R.J., Ball M.J., Colhuon E.H. Evidence for high affinity choline transport in synaptosomes prepared from hippocampus and neocortex of patients with Alzheimer's disease. Brain Res 1983, 289:169-175.
103. Salehi A., Verhaagen J., Dijkhuizen P.A., Swaab D.F. Co-localization of high affinity neurotrophin receptors in nucleus basalis of Meynert neurons and their differential reduction in Alzheimer's disease. Neuroscience 1996, 75:373-387.
104. Sarter M., Bruno J.P. Mild cognitive impairment and the cholinergic hypothesis: a very different take on recent data. Ann Neurol 2002, 52:384-385.
105. Schmitz C., Rutten B.P.F., Pielen A., Schafer S., Wirths O., Tremp J., et al. Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease. Am J Pathol 2004, 164:1495-1502.
106. Schroder H., Giacobini E., Strubble R.G., Zilles K., Maelicke A. Nicotinic cholinoceptive neurons of the frontal cortex are reduced in Alzheimer's disease. Brain Res Bull 1991, 27:631-636.
107. Scott S.A., Mufson E.J., Weingartner J.A., Skau K.A., Crutcher K.A. Nerve growth factor in Alzheimer's disease: increased levels throughout the brain coupled with declines in nucleus basalis. J Neurosci 1995, 15:6213-6221.
108. Seltzer B. Cholinesterase inhibitors in the clinical management of Alzheimer's disease: importance of early and persistent treatment. J Int Med Res 2006, 34:339-347.
109. Seo H., Isacson O. Abnormal APP, cholinergic and cognitive function in Ts65Dn Down's model mice. Exp Neurol 2005, 193:469-480.
110. Sheu K.F., Kim Y.T., Blass J.P., Wecksler M.E. An immunochemical study of the pyruvate dehydrogenase deficit in Alzheimer's disease brain. Ann Neurol 1985, 17:444-449.
111. Smith C., Swash M. Possible biochemical basis of memory disorders in Alzheimer's disease. Ann Neurol 1978, 3:471-473.
112. Smith D.E., Roberts J., Gage F.H., Tuszynski M.H. Age-associated neuronal atrophy occurs in the primate brain and is reversible by growth factor gene therapy. Proc Natl Acad Sci USA 1999, 96:10893-10898.
113. Sofroniew M.V., Howe C.L., Mobley W.C. Nerve growth factor signaling, neuroprotection and neural repair. Annu Rev Neurosci 2001, 24:1217-1281.
114. Sparks D.L., Hunsaker J.C., Slevin J.T., DeKosky S.T., Kryscio R.J., Markesberry W.R. Monoaminergic and cholinergic synaptic markers in the nucleus basalis of Meynert (nbM): normal age-related changes and the effect of heart disease and Alzheimer's disease. Ann Neurol 1992, 31:611-620.
115. Stanfield B.B., Cowan M.W. The sprouting of septal afferents to the dentate gyrus after lesions of the entorhinal cortex in adult rats. Brain Res 1982, 232:162-170.
116. Takeuchi A., Irizzarry M.C., Duff K., Saido T.C., Hsiao Ashe K., Hasegawa M., et al. Age related amyloid β deposition in transgenic mice overexpressing both Alzheimer's mutant presenilin 1 and amyloid β precursor protein Swedish mutant, is not associated with global neuronal loss. Am J Pathol 2000, 157:331-339.
117. Terry A.V., Buccafusco J.J. The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther 2003, 306:821-827.
118. Tiraboschi P., Hansen L.A., Alford M., Masliah E., Thal L.J., Corey-Bloom J. The decline in synapses and cholinergic activity in asynchronous Alzheimer's disease. Neurology 2000, 55:1278-1283.
119. Ulrich J., Johannson-Locher G., Seiler W.O., Stahelin H.B. Does smoking protect from Alzheimer's disease? Alzheimer-type changes in 301 unselected brains from patients with known smoke history. Acta Neuropathol (Berl) 1997, 94:450-454.
120. Van Leuven F. Single and multiple transgenic mice as models for Alzheimer's disease. Prog Neurobiol 2000, 61:306-312.
121. Virgili M., Monti B., Polazzi E., Angiolini G., Contestabile A. Topography of neurochemical alterations in the CNS of aged rats. Int J Dev Neurosci 2001, 19:109-116.
122. Waller S.B., Ball M.J., Reynolds M.A., London E.D. Muscarinic binding and choline acetyltransferase in postmortem brain of demented patients. Can J Neurol Sci 1986, 13:528-532.
123. Wenk G., Harrington C., Tucker D., Rance N., Walker N. Basal forebrain neurons and memory: a biochemical, histological and behavioral study of differential vulnerability to ibotenate and quisqualate. Behav Neurosci 1992, 106:909-923.
124. Wenk G., Stoehr J., Quintana G., Mobley S., Wiley R. Behavioral, biochemical, histological and electrophysiological effects of 192 IgG-saporin injections into the basal forebrain of rats. J Neurosci 1994, 14:5986-5995.
125. Whitehouse P.J., Price D.L., Struble R.G., Clark A.W., Coyle J.T., Delon M.R. Alzheimer's disease and senile dementia: loss of neurones in basal forebrain. Science 1982, 217:408-417.
126. Wilcock G.K., Esiri M.M., Bowen D.M., Smith C.C. Alzheimer's disease. Correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities. J Neurol Sci 1982, 57:407-417.
127. Wiley R.G., Oeltmann T.N., Lappi D.A. Immunolesioning: selective destruction of neurons using immunotoxin to rat NGF receptor. Brain Res 1991, 562:149-153.
128. Wisniewski K.E., Wisniewski H.M., Wen G.Y. Occurrence of neuropathological changes and dementia in Alzheimer's disease and Down's syndrome. Ann Neurol 1985, 17:278-282.
129. Wong T.P., Debeir T., Duff K., Cuello A.C. Reorganization of cholinergic terminals in the cerebral cortex and hippocampus in transgenic mice carrying mutated presenilin-1 and amyloid precursor protein transgenes. J Neurosci 1999, 19:2706-2716.